In a recent turn of events, the Supreme Court has set aside the order for revocation of Sugen/Pfizer’s patent (Sunitinib/Sutent) as passed by the Controller of the Indian Patent Office in a recent post grant opposition proceedings brought forth by Cipla on the grounds of obviousness and lack of inventive step. The revocation of the granted patent was made on the basis of comparative testsas carried out between the compounds of the claimed invention and the compounds of the closest prior art![]()
